News

The two companies have entered into a multi-year research and development collaboration to develop the vaccines for a maximum of five undisclosed infectious disease pathogens. As per the

Tagrisso is a third-generation and irreversible EGFR-TKI designed to suppress both EGFR-sensitising and EGFR T790M-resistance mutations, with clinical activity against CNS metastases. The approval was based on data

Cellenkos submitted its IND application on May 11, 2018.  The Phase I clinical trial of CK0801 will commence in the third quarter of 2018 at The University of

Results were presented at the OxalEurope, European Hyperoxaluria Consortium, taking place on 8 June 2018 in Naples, Italy. Updated interim data were from Part B of the Phase

The approval for the drug regimen is for CLL and SLL patients, with or without 17p deletion, and who had received more than one prior therapy. Venclexta is

Oncologie is committed to developing impactful cancer therapies to improve long–term survival of cancer patients worldwide. Building a pipeline of First and Best-in-Class clinical stage drug candidates through

Alliance awaits issue of the formal Marketing Authorisation from the MHRA in the coming weeks, with UK launch anticipated to be in the autumn of this year. Diclectin,

Considered to be potentially life-threatening, pemphigus vulgaris is an autoimmune blistering disease that affects the skin and mucous membranes. Patients with this condition suffer from progressive painful blistering

Through using LentiVector platform, Oxford BioMedica has developed OXB-102 gene therapy for Parkinson’s disease. OXB-102, now renamed AXO-Lenti-PD, is a lentiviral gene therapy with a clinically validated mechanism